Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
6427 | 1419 | 33.0 | 52% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1446 | 7310 | LEVOSIMENDAN//CALCIUM SENSITIZERS//CALCIUM SENSITIZER |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | FLOSEQUINAN | Author keyword | 29 | 72% | 2% | 23 |
2 | BTS 53 554 | Author keyword | 1 | 100% | 0% | 2 |
3 | FIRST DOSE HYPOTENSION | Author keyword | 1 | 50% | 0% | 2 |
4 | NEUROHUMORAL MECHANISMS | Author keyword | 1 | 50% | 0% | 2 |
5 | VASODILATOR THERAPY | Author keyword | 1 | 18% | 0% | 7 |
6 | ALACEPRIL | Author keyword | 1 | 21% | 0% | 3 |
7 | CARDIORENAL HEMODYNAMICS | Author keyword | 1 | 50% | 0% | 1 |
8 | CAS 395 28 8 | Author keyword | 1 | 50% | 0% | 1 |
9 | CAS 76568 02 0 | Author keyword | 1 | 50% | 0% | 1 |
10 | CONGESTIVE HEART FAILURE DRUG THERAPY | Author keyword | 1 | 50% | 0% | 1 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | FLOSEQUINAN | 29 | 72% | 2% | 23 | Search FLOSEQUINAN | Search FLOSEQUINAN |
2 | BTS 53 554 | 1 | 100% | 0% | 2 | Search BTS+53+554 | Search BTS+53+554 |
3 | FIRST DOSE HYPOTENSION | 1 | 50% | 0% | 2 | Search FIRST+DOSE+HYPOTENSION | Search FIRST+DOSE+HYPOTENSION |
4 | NEUROHUMORAL MECHANISMS | 1 | 50% | 0% | 2 | Search NEUROHUMORAL+MECHANISMS | Search NEUROHUMORAL+MECHANISMS |
5 | VASODILATOR THERAPY | 1 | 18% | 0% | 7 | Search VASODILATOR+THERAPY | Search VASODILATOR+THERAPY |
6 | ALACEPRIL | 1 | 21% | 0% | 3 | Search ALACEPRIL | Search ALACEPRIL |
7 | CARDIORENAL HEMODYNAMICS | 1 | 50% | 0% | 1 | Search CARDIORENAL+HEMODYNAMICS | Search CARDIORENAL+HEMODYNAMICS |
8 | CAS 395 28 8 | 1 | 50% | 0% | 1 | Search CAS+395+28+8 | Search CAS+395+28+8 |
9 | CAS 76568 02 0 | 1 | 50% | 0% | 1 | Search CAS+76568+02+0 | Search CAS+76568+02+0 |
10 | CONGESTIVE HEART FAILURE DRUG THERAPY | 1 | 50% | 0% | 1 | Search CONGESTIVE+HEART+FAILURE++DRUG+THERAPY | Search CONGESTIVE+HEART+FAILURE++DRUG+THERAPY |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | BTS 49465 | 17 | 100% | 1% | 8 |
2 | ARTERIOVENOUS DILATING AGENT | 6 | 100% | 0% | 4 |
3 | VASODILATOR THERAPY | 5 | 11% | 3% | 40 |
4 | CONGESTIVE CARDIAC FAILURE | 5 | 29% | 1% | 14 |
5 | HYDRALAZINE ISOSORBIDE DINITRATE | 4 | 67% | 0% | 4 |
6 | VASODILATOR DRUG | 3 | 57% | 0% | 4 |
7 | HEMODYNAMIC ABNORMALITIES | 2 | 26% | 1% | 8 |
8 | HEMODYNAMIC MEASUREMENTS | 2 | 24% | 1% | 8 |
9 | FUNCTIONAL RENAL INSUFFICIENCY | 1 | 31% | 0% | 4 |
10 | FLOSEQUINAN | 1 | 16% | 0% | 7 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
MANAGEMENT OF HEART-FAILURE .1. PHARMACOLOGICAL TREATMENT | 1994 | 54 | 22 | 59% |
RENAL AND ELECTROLYTE COMPLICATIONS OF CONGESTIVE-HEART-FAILURE AND EFFECTS OF THERAPY WITH ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS | 1992 | 40 | 69 | 77% |
CARDIOMYOPATHY OF OVERLOAD - A MAJOR DETERMINANT OF PROGNOSIS IN CONGESTIVE HEART-FAILURE | 1990 | 442 | 86 | 14% |
HOW SHOULD PHYSICIANS VIEW HEART-FAILURE - THE PHILOSOPHICAL AND PHYSIOLOGICAL EVOLUTION OF 3 CONCEPTUAL MODELS OF THE DISEASE | 1993 | 38 | 57 | 32% |
ROLE OF NEUROHORMONAL MECHANISMS IN DETERMINING SURVIVAL IN PATIENTS WITH SEVERE CHRONIC HEART-FAILURE | 1987 | 184 | 70 | 49% |
THE NEUROHUMORAL AXIS IN CONGESTIVE HEART-FAILURE | 1984 | 477 | 51 | 37% |
VASCULAR TONE IN HEART-FAILURE - THE NEUROENDOCRINE-THERAPEUTIC INTERFACE | 1991 | 17 | 33 | 61% |
VASODILATOR AND INOTROPIC DRUGS FOR THE TREATMENT OF CHRONIC HEART-FAILURE - DISTINGUISHING HYPE FROM HOPE | 1988 | 117 | 167 | 38% |
Adverse effects of ACE inhibitors in patients with chronic heart failure and/or ventricular dysfunction - Meta-analysis of randomised clinical trials | 2003 | 4 | 88 | 32% |
Alterations in the prognosis of chronic heart failure: An overview of the major mortality trials | 1997 | 11 | 18 | 33% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | SECT HEART FAILURE TRANSPLANT | 1 | 50% | 0.1% | 1 |
2 | UNIT PHARMACOEPIDEMIOL PHARMACOECON PE | 1 | 50% | 0.1% | 1 |
3 | WATFORD RD | 1 | 50% | 0.1% | 1 |
4 | 5400 GOUIN BLVD W | 0 | 25% | 0.1% | 1 |
5 | SECT ADV HEART FAILURE CARDIAC TRANSPLANTAT | 0 | 17% | 0.1% | 1 |
6 | ANMCO | 0 | 14% | 0.1% | 1 |
7 | MICHIGAN HEART FAILURE TRANSPLANT CARE | 0 | 13% | 0.1% | 1 |
8 | MILTON S HERSHEY MED MED MED | 0 | 13% | 0.1% | 1 |
9 | CARDIOMYOPATHY HEART TRANSPLANTAT | 0 | 10% | 0.1% | 1 |
10 | CLIN PHARMACOL CARDIOL | 0 | 10% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000182442 | IBOPAMINE//EPININE//NOLOMIROLE |
2 | 0.0000164217 | CHRONIC VOLUME LOAD//CARBON 13 LABELED SUBSTRATES//CLIN PHARMACOL INTERNAL PROPEDEUT |
3 | 0.0000151330 | ZOFENOPRIL//INFARCT EXPANSION//ANGIOTENSIN II AT1 RECEPTOR BLOCKADE |
4 | 0.0000137311 | CAS 89396 94 1//TA 6366//MOEXIPRIL |
5 | 0.0000128489 | XAMOTEROL//EPANOLOL//DENOPAMINE |
6 | 0.0000117674 | ENOXIMONE//AMRINONE//MILRINONE |
7 | 0.0000115939 | ENDOTHELIAL RESPONSES//RADIAL ARTERY DIAMETER//RAPID VENTRICULAR PACING |
8 | 0.0000098376 | DIGOXIN//DIGOXIN TOXICITY//SERUM DIGOXIN CONCENTRATION |
9 | 0.0000092248 | CARVEDILOL//BUCINDOLOL//CARVEDILOL ENANTIOMERS |
10 | 0.0000089000 | CHRONIC HEART FAILURE//VENTILATORY EXPIRED GAS//CARDIOPULMONARY EXERCISE TESTING |